Eli Lilly and Company $LLY Shares Bought by Venture Visionary Partners LLC

Key Points

• Venture Visionary Partners LLC increased its stake in Eli Lilly and Company by 16.6%, owning 12,046 shares valued at approximately $9.39 million as of the latest SEC filing.
• Recent insider activity includes Daniel Skovronsky, EVP, purchasing 1,000 shares for $634.40 each, increasing his ownership to 137,660 shares worth roughly $87.33 million.
• Wall Street analysts have given Eli Lilly a mixed outlook, with one analyst labeling it a Strong Buy while others have varying ratings and a target price average of $939.61 per share.

Venture Visionary Partners LLC grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,046 shares of the company's stock after purchasing an additional 1,712 shares during the period. Venture Visionary Partners LLC's holdings in Eli Lilly and Company were worth $9,390,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Hobbs Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after acquiring an additional 12 shares in the last quarter. Hixon Zuercher LLC grew its position in shares of Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after purchasing an additional 12 shares during the last quarter. O Brien Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC grew its position in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners grew its position in shares of Eli Lilly and Company by 2.7% in the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock valued at $407,000 after purchasing an additional 13 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jamere Jackson bought 200 shares of the stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $939.61.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $725.54 on Tuesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The firm has a 50 day moving average of $733.42 and a 200-day moving average of $765.98. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $686.69 billion, a P/E ratio of 47.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.